Latest News and Events

July 7, 2014

Personalized Cellular Therapy for Leukemia Receives FDA's Breakthrough Therapy Designation

A personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL). The investigational therapy, known as CTL019, is the first personalized cellular therapy for the treatment of cancer to receive this important classification.

In early-stage clinical trials at the Hospital of the University of Pennsylvania and The Children's Hospital of Philadelphia, 89 percent of ALL patients who were not responding to conventional therapies went into complete remission after receiving CTL019.

Read the press release on the Wall Street Journal's Marketwatch.

  • Print
  • Share

Contact Us